June Park, Ph.D., serves as the CEO of siRNAgen Therapeutics, a clinical-stage platform biotech specializing in RNAi therapeutics for immunology and CNS conditions. Prior to siRNAgen, June served as a healthcare consultant at Putnam Associates, providing commercial and product development strategies to global biopharmaceutical companies on oncology and rare disease portfolios throughout their product life cycles. A Gates Scholar, June began her academic journey at MIT, where she made notable strides in RNAi delivery technologies at the Langer Lab and later, at the University of Cambridge, pioneered innovative supramolecular biomaterials. A Class of 2023 Termeer Fellow, June is a passionate advocate of patient-centricity and equal opportunities. She holds a B.S. in Chemical and Biological Engineering with minor in Biology and Music Performance from MIT and a Ph.D. in Chemistry from the University of Cambridge.